Dupilumab in Chronic Spontaneous Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

July 7, 2021

Study Completion Date

July 7, 2021

Conditions
Chronic Spontaneous UrticariaRecurrent Angioedema
Interventions
DRUG

Dupilumab

anti-IL4-Receptor alpha

DRUG

Placebo

Placebo

Trial Locations (6)

10117

Charite University, Berlin, Germany, Berlin

35043

Universitätsklinikum Giessen und Marburg, Marburg

48149

Hautklinik Universitätsklinikum Münster, Münster

55101

Hautklinik der Universitätsmedizin Mainz Clinical Research Center, Mainz

01307

Universitätsklinikum Carl Gustav Carus, Dresden

04103

Universitätsmedizin Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, Leipzig

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Proinnovera GmbH

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER